ASH: HuMax-CD38 effective in preclinical studies

Genmab A/S (CSE: GEN - News) announced today that HuMax®-CD38 was effective in killing primary multiple myeloma cells and plasma cell leukemia cells in preclinical studies. HuMax-CD38 is a human IgG1k antibody that targets the CD38 molecule which is highly expressed on the surface of multiple myeloma tumor cells.